StockData
AstraZeneca PLC logo

AstraZeneca PLC

AZNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 12/30
$163.95−1.46 (-0.88%)

Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%

AstraZeneca Respiratory & Immunology (R&I) by Quarter

Respiratory & Immunology (R&I) — Worldwide product sales ($M) ($M)

QuarterlyAnnual

AstraZeneca Respiratory & Immunology (R&I): $2,207M in Q2 2026, up 11.0% from a year earlier. That is the highest of the 42 quarters on record here.

Latest, Q2 2026
2,207
Period ended Jun 30, 2026
Change on a year earlier
+11.0%
1,988 in Q2 2025
History
42 quarters
Since Q1 2016
Sources
27
Documents cited below

Where the Q2 2026 figure comes from

“|| R&I | 2,207 | | 11 | | 9 | | 982 | | - | | 490 | | 29 | | 24 | | 509 | | 21 | | 16 | | 226 | | 9 | | 11”

Source: Form 6-K FY2026Q2 Earnings Release ↗

Reported in Form 6-K Quarterly & Form 20-F Product Sales by Therapy Area & Region Tables.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedRespiratory & Immunology (R&I) — Worldwide product sales ($M) ($M)Year on yearSource
Q2 2026Jun 30, 20262,207+11.0%Form 6-K FY2026Q2 Earnings Release ↗
Q1 2026Mar 31, 20262,150+10.4%Form 6-K FY2026Q1 Earnings Release ↗
Q4 2025Dec 31, 20252,147+8.2%Form 6-K FY2025Q4 Earnings Release ↗
Q3 2025Sep 30, 20252,085+13.9%Form 6-K FY2025Q3 Earnings Release ↗
Q2 2025Jun 30, 20251,988+10.6%Form 6-K FY2025Q2 Earnings Release ↗
Q1 2025Mar 31, 20251,947+7.9%Form 6-K FY2025Q1 Earnings Release ↗
Q4 2024Dec 31, 20241,985+24.8%Form 6-K FY2024Q4 Earnings Release ↗
Q3 2024Sep 30, 20241,830+26.1%Form 6-K FY2024Q3 Earnings Release ↗
Q2 2024Jun 30, 20241,797+21.2%Form 6-K FY2024Q2 Earnings Release ↗
Q1 2024Mar 31, 20241,804+14.0%Form 6-K FY2024Q1 Earnings Release ↗
Q4 2023Dec 31, 20231,590+9.9%Form 6-K FY2023Q4 Earnings Release ↗
Q3 2023Sep 30, 20231,451+1.7%Form 6-K FY2023Q3 Earnings Release ↗
Q2 2023Jun 30, 20231,483+7.4%Form 6-K FY2023Q2 Earnings Release ↗
Q1 2023Mar 31, 20231,583+4.9%Form 6-K FY2023Q1 Earnings Release ↗
Q4 2022Dec 31, 20221,447-9.0%Form 6-K FY2022Q4 Earnings Release ↗
Q3 2022Sep 30, 20221,427-3.8%Form 6-K FY2022Q3 Earnings Release ↗

Breakdown

What makes up respiratory & Immunology (R&I)

Cite this data

StockData. (2026). AstraZeneca Respiratory & Immunology (R&I) ($M), quarterly Q1 2016–Q2 2026 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/ta-ri-world

See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.